External validation of the PROGRESS-CTO perforation risk score: Individual patient data pooled analysis of three registries.

chronic total occlusion external validation major adverse cardiovascular events mortality percutaneous coronary intervention prediction risk model

Journal

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139

Informations de publication

Date de publication:
08 Jan 2023
Historique:
revised: 05 01 2023
received: 02 11 2022
accepted: 31 12 2022
entrez: 8 1 2023
pubmed: 9 1 2023
medline: 9 1 2023
Statut: aheadofprint

Résumé

Coronary artery perforation is one of the most feared and common complications of chronic total occlusion (CTO) percutaneous coronary intervention (PCI). To assess the usefulness of the recently developed PROGRESS-CTO (NCT02061436) perforation risk score in independent cohorts. Individual patient-level data pooled analysis of three registries was performed. Of the 4566 patients who underwent CTO PCI at 25 centers, 196 (4.2%) had coronary artery perforation. Patients with perforations were older (69 ± 10 vs. 65 ± 10, p < 0.001), more likely to be women (19% vs. 13%, p = 0.009), more likely to have a history of prior coronary artery bypass graft (34% vs. 20%, p < 0.001), and unfavorable angiographic characteristics such as blunt stump (62% vs. 48%, p < 0.001), proximal cap ambiguity (52% vs. 34%, p < 0.001), and moderate-severe calcification (60% vs. 49%, p = 0.002). Technical success was lower in patients with perforations (73% vs. 88%, p < 0.001). The area under the receiver operating characteristic curve of the PROGRESS-CTO perforation risk model was 0.76 (95% confidence interval [CI], 0.72-0.79), with good calibration (Hosmer-Lemeshow p = 0.97). We found that the CTO PCI perforation risk increased with higher PROGRESS-CTO perforation scores: 0.3% (score 0), 2.3% (score 1), 3.1% (score 2), 5.5% (score 3), 7.5% (score 4), 14.6% (score 5). Given the good discriminative performance, calibration, and the ease of calculation, the PROGRESS-CTO perforation score may facilitate assessment of the risk of perforation in patients undergoing CTO PCI.

Sections du résumé

BACKGROUND BACKGROUND
Coronary artery perforation is one of the most feared and common complications of chronic total occlusion (CTO) percutaneous coronary intervention (PCI).
METHODS METHODS
To assess the usefulness of the recently developed PROGRESS-CTO (NCT02061436) perforation risk score in independent cohorts. Individual patient-level data pooled analysis of three registries was performed.
RESULTS RESULTS
Of the 4566 patients who underwent CTO PCI at 25 centers, 196 (4.2%) had coronary artery perforation. Patients with perforations were older (69 ± 10 vs. 65 ± 10, p < 0.001), more likely to be women (19% vs. 13%, p = 0.009), more likely to have a history of prior coronary artery bypass graft (34% vs. 20%, p < 0.001), and unfavorable angiographic characteristics such as blunt stump (62% vs. 48%, p < 0.001), proximal cap ambiguity (52% vs. 34%, p < 0.001), and moderate-severe calcification (60% vs. 49%, p = 0.002). Technical success was lower in patients with perforations (73% vs. 88%, p < 0.001). The area under the receiver operating characteristic curve of the PROGRESS-CTO perforation risk model was 0.76 (95% confidence interval [CI], 0.72-0.79), with good calibration (Hosmer-Lemeshow p = 0.97). We found that the CTO PCI perforation risk increased with higher PROGRESS-CTO perforation scores: 0.3% (score 0), 2.3% (score 1), 3.1% (score 2), 5.5% (score 3), 7.5% (score 4), 14.6% (score 5).
CONCLUSION CONCLUSIONS
Given the good discriminative performance, calibration, and the ease of calculation, the PROGRESS-CTO perforation score may facilitate assessment of the risk of perforation in patients undergoing CTO PCI.

Identifiants

pubmed: 36617391
doi: 10.1002/ccd.30551
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : The authors are grateful for the philanthropic support of our generous anonymous donors, and the philanthropic support of Drs. Mary Ann and Donald A Sens; Mrs. Diane and Dr. Cline Hickok; Mrs. Wilma and Mr. Dale Johnson; Mrs. Charlotte and Mr. Jerry Golinvaux Family Fund; the Roehl Family Foundation; the Joseph Durda Foundation. The generous gifts of these donors to the Minneapolis Heart Institute Foundation's Science Center for Coronary Artery Disease (CCAD) helped support this research project

Informations de copyright

© 2023 Wiley Periodicals LLC.

Références

Kostantinis S, Simsek B, Karacsonyi J, et al. In-hospital outcomes and temporal trends of percutaneous coronary interventions for chronic total occlusion. EuroIntervention. 2022;18:e929-e932.
Kostantinis S, Simsek B, Karacsonyi J, et al. Incidence, mechanisms, treatment, and outcomes of coronary artery perforation during chronic total occlusion percutaneous coronary intervention. Am J Cardiol. 2022;182:17-24.
Karacsonyi J, Vemmou E, Nikolakopoulos ID, Ungi I, Rangan BV, Brilakis ES. Complications of chronic total occlusion percutaneous coronary intervention. Neth Heart J. 2021;29(1):60-67.
Kostantinis S, Simsek B, Karacsonyi J, et al. Development and validation of a scoring system for predicting clinical coronary artery perforation during percutaneous coronary intervention of chronic total occlusions: the PROGRESS-CTO perforation score. EuroIntervention. Published online October 24, 2022. https://pubmed.ncbi.nlm.nih.gov/36281650/
Azzalini L, Ojeda S, Karatasakis A, et al. Long-Term outcomes of percutaneous coronary intervention for chronic total occlusion in patients who have undergone coronary artery bypass grafting vs those who have not. Can J Cardiol. 2018;34(3):310-318.
Azzalini L, Ojeda S, Demir OM, et al. Recanalization of chronic total occlusions in patients with vs without chronic kidney disease: the impact of Contrast-Induced acute kidney injury. Can J Cardiol. 2018;34(10):1275-1282.
Maeremans J, Walsh S, Knaapen P, et al. The hybrid algorithm for treating Chronic Total occlusions in Europe. JACC. 2016;68(18):1958-1970.
Ybarra LF, Rinfret S, Brilakis ES, et al. Definitions and clinical trial design principles for coronary artery chronic total occlusion therapies: CTO-ARC consensus recommendations. Circulation. 2021;143(5):479-500.
Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33(20):2551-2567.
Morino Y, Abe M, Morimoto T, et al. Predicting successful guidewire crossing through chronic total occlusion of native coronary lesions within 30 minutes. JACC Cardiovasc Interv. 2011;4(2):213-221.
Azzalini L, Carlino M, Bellini B, et al. Long-term outcomes of chronic total occlusion recanalization versus percutaneous coronary intervention for complex non-occlusive coronary artery disease. Am J Cardiol. 2020;125(2):182-188.
Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American college of Cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 2022;145(3):e4-e17.
Simsek B, Kostantinis S, Karacsonyi J, et al. A systematic review and Meta-Analysis of clinical outcomes of patients undergoing chronic total occlusion percutaneous coronary intervention. J Invasive Cardiol. 2022;34:E763-E775.
Lee SW, Lee PH, Ahn JM, et al. Randomized trial evaluating percutaneous coronary intervention for the treatment of chronic total occlusion. Circulation. 2019;139(14):1674-1683.
Werner GS, Martin-Yuste V, Hildick-Smith D, et al. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J. 2018;39(26):2484-2493.
Azzalini L, Karmpaliotis D, Santiago R, et al. Contemporary issues in chronic total occlusion percutaneous coronary intervention. JACC Cardiovasc Interv. 2022;15(1):1-21.
Azzalini L. The new PROGRESS-CTO complication scores. JACC Cardiovasc Interv. 2022;15(14):1423-1426.
Simsek B, Kostantinis S, Karacsonyi J, et al. Predicting periprocedural complications in chronic total occlusion percutaneous coronary intervention. JACC Cardiovasc Interv. 2022;15(14):1413-1422.

Auteurs

Bahadir Simsek (B)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA.

Peter Tajti (P)

The Gottsegen National Cardiovascular Center, Budapest, Hungary.

Mauro Carlino (M)

Interventional Cardiology Division, Cardio-Thoracic-Vascular Department, San Raffaele Scientific Institute, Milan, Italy.

Soledad Ojeda (S)

Division of Interventional Cardiology, Reina Sofia Hospital, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), University of Cordoba, Cordoba, Spain.

Manuel Pan (M)

Division of Interventional Cardiology, Reina Sofia Hospital, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), University of Cordoba, Cordoba, Spain.

Stephane Rinfret (S)

Emory Heart and Vascular Center, Emory University School of Medicine, Atlanta, Georgia, USA.

Evangelia Vemmou (E)

Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

Spyridon Kostantinis (S)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA.

Ilias Nikolakopoulos (I)

Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

Judit Karacsonyi (J)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA.

Athanasios Rempakos (A)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA.

Joseph A Dens (JA)

Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.

Pierfrancesco Agostoni (P)

Hartcentrum, Ziekenhuis Netwerk Antwerpen Middelheim, Antwerp, Belgium.

Khaldoon Alaswad (K)

Henry Ford Health System, Detroit, Michigan, USA.

Michael Megaly (M)

Division of Cardiology, Willis Knighton Heart Institute, Shreveport, Louisiana, USA.

Alexandre Avran (A)

Department of Interventional Cardiology, Clinique Pasteur, Essey-lès-Nancy, Toulouse, France.

James W Choi (JW)

Division of Cardiology, Texas Health Presbyterian Hospital, Dallas, Texas, USA.

Farouc A Jaffer (FA)

Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Darshan Doshi (D)

Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Dimitri Karmpaliotis (D)

Morristown Medical Center, Morristown, New Jersey, USA.

Jaikirshan J Khatri (JJ)

Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Paul Knaapen (P)

Department of Cardiology, VU University Medical Center, Amsterdam, the Netherlands.

Alessio La Manna (A)

University of Catania, Catania, Italy.

James C Spratt (JC)

St. George's University Healthcare NHS Trust, London, UK.

Masaki Tanabe (M)

Department of Cardiology, Nozaki Tokushukai Hospital, Osaka, Japan.

Simon Walsh (S)

Belfast Health, Belfast, UK.

Olga C Mastrodemos (OC)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA.

Salman Allana (S)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA.

Bavana V Rangan (BV)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA.

Omer Goktekin (O)

Division of Cardiology, Memorial Bahcelievler Hospital, Istanbul, Turkey.

Sevket Gorgulu (S)

Division of Cardiology, Biruni University School of Medicine, Istanbul, Turkey.

Paul Poommipanit (P)

University Hospitals, Cleveland, Ohio, USA.

Kathleen E Kearney (KE)

Division of Cardiology, University of Washington, Seattle, Washington, USA.

William L Lombardi (WL)

Division of Cardiology, University of Washington, Seattle, Washington, USA.

J Aaron Grantham (JA)

Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA.

Kambis Mashayekhi (K)

Division of Cardiology and Angiology II, University Heart Center Freiburg - Bad Krozingen, Bad Krozingen, Germany.
Department for Internal Medicine and Cardiology, Heart center Lahr, Lahr, Germany.

Emmanouil S Brilakis (ES)

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA.

Lorenzo Azzalini (L)

Division of Cardiology, University of Washington, Seattle, Washington, USA.

Classifications MeSH